Long-acting il-15 and uses thereof

By mutating and fusing the amino acid sequence of the IL-15 protein to form a heterodimeric fusion protein, the problem of short half-life and high toxicity of IL-15 therapy was solved, the proliferation efficacy of NK cells and CD8+ T cells was improved, and the anti-tumor efficacy was enhanced.

CN116134140BActive Publication Date: 2026-03-17SHANGHAI WUXI BIOLOGIC TECH CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-09-01
Publication Date
2026-03-17

Smart Images

  • Figure CN116134140B_ABST
    Figure CN116134140B_ABST
Patent Text Reader

Abstract

The present disclosure provides IL-15 variants and heterodimeric IL-15 / IL-15Rα-Fc fusion proteins comprising the IL-15 variants, methods of producing the same, and uses thereof. The provided IL-15 variants and fusion proteins can be effective agents for treating cancer.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Recombinant DNA methods, vectors and host cells

    EP0338841A1

  • IL15 / IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS

    US20180118805A1

  • Method for making heteromultimeric polypeptides

    US5731168A

  • Recombinant DNA sequences, vectors containing them and method for the use thereof

    WO1987004462A1

  • Recombinant DNA expression vectors

    WO1989001036A1